One of the most fascinating aspects of a career in cancer research is that one never knows when or where the next great discovery will occur. This was true of a recent breakthrough discovery made by the Dr. Russell Ryan laboratory at the University of Michigan Medical School.
Members of the University of Michigan Department of Pathology and Michigan Center for Translational Pathology, in collaboration with the Clinical Proteomic Tumor Analysis Consortium, recently published a large study on clear cell renal cell carcinomas (ccRCCs), which represent about 75% of the RCC cases and account for the most RCC-associated deaths.
Dr. Robertson Davenport was recently interviewed regarding the new Blood Bank at Michigan Medicine. The renovation of space in the University Hospital was recently completed and the Blood Bank relocated to its new site, designed using Lean Facility principles.
Blood banks need a constant supply of deposits to meet the needs of patients with cancer, traumatic injuries, failing organs, blood diseases, and more. Deep inside the main University of Michigan hospital lies a gleaming new bank, devoted to handling priceless treasure and storing it safely.
The University of Michigan Rogel Cancer Center researchers received one of the Prostate Cancer Foundation’s four inaugural Class of 2022 TACTICAL (Therapy Acceleration To Intercept Cancer Lethality) Award. This $30 million program will support cross-disciplinary pioneering research toward the goal of developing 21st Century therapies for the most life-threatening form of prostate cancer.
For many of us, the idea of having blood drawn can be an unnerving thought. The use of needles and the sight of blood itself is not something we look forward to.
Walk through a 30-year career with Dr. Gabriel Núñez—highlighting his key discoveries, perspectives on work/life balance, and those he mentored.
The diagnosis of metastatic prostatic cancer (MPC) by fine needle aspiration (FNA) can usually be rendered by examining the cells’ shape and appearance under a microscope (its cytomorphology) and through features seen in immunohistochemical (IHC) testing.
The Celina Kleer lab at the University of Michigan Department of Pathology and Rogel Cancer Center has found a new mechanism that fuels metastasis in triple negative breast cancers. In their new study they show that EZH2, a master regulator of cell type identity, known to function through methylation of histones, has a new, unexpected function in aggressive breast cancers. By adding methyl groups to the p38 protein, EZH2 enhances the ability of breast cancer cells to spread to other tissue throughout the body, a process known as metastasis.
On Thursday, July 15, Scott Marquette, Associate Chief Operating Officer from Michigan Medicine, visited the Clinical Microbiology laboratory at the Department of Pathology. The purpose of the visit was to learn more about the Visual Inventory Management pilot, a new initiative that is intended to help lab staff better organize their tools, resources and assets within the lab setting.